Clinical Trial

Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease

Name: Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease — clinical trial record (NCT07187167)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.

Trial Details

NCT Number	NCT07187167
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions	Rosai-Dorfman Disease
Enrollment	40 participants
Start Date	2025-04-12
Primary Completion	2027-04-12 (estimated)
Study Completion	2027-04-12 (estimated)
Updated on ClinicalTrials.gov	2025-09-22